期刊文献+

HTRA1 shRNA慢病毒表达载体的构建及感染RPE细胞株的鉴定

Construction of a lentiviral vector of HTRA1 shRNA and identification of its RNA interference effect in a RPE cell line
原文传递
导出
摘要 目的构建HTRA1基因的shRNA慢病毒表达载体,并鉴定HTRA1 shRNA慢病毒感染RPE细胞株的效果。设计实验研究。研究对象HTRA1 shRNA慢病毒载体和RPE细胞。方法设计靶向HTRA1 mRNA的寡核苷酸序列,构建HTRA1 shRNA表达质粒,测序鉴定其序列的正确性。通过载体质粒pGC-LV与辅助质粒pHelper 1.0、pHelper 2.0共转染293T细胞包装慢病毒,收集病毒上清,测定滴度。将包装好的HTRA1 shRNA慢病毒感染RPE细胞,设阴性对照和空白对照,采用实时PCR(RT-PCR)和蛋白印迹法(Western Blot)方法检测HTRA1基因的mRNA水平和蛋白质表达水平的变化。主要指标HTRA1基因的mRNA和蛋白质表达量。结果 DNA测序证实HTRA1 shRNA表达质粒包装了正确的RNA干扰序列。慢病毒滴度测定为8×108TU/ml。HTRA1 shRNA慢病毒感染RPE细胞后,HTRA1基因的mRNA水平和蛋白质表达水平较空白对照组和阴性对照组均明显下降,差异均有统计学意义。结论成功构建了HTRA1 shRNA的慢病毒表达载体,该shRNA慢病毒能够有效地抑制RPE细胞株HTRA1基因的表达。 Objective This study was aimed to construct lentivirus-mediated shRNA expression vector targeting HTRA 1 and iden- tify the RNA interference effect in a RPE cell line. Design Experimental study. Participants HTRA 1 shRNA lentivirus vector and RPE cells. Method One pair of oligonucleotide sequences targeted at human HTRA 1 mRNA was designed and synthesized. The annealed oligonucleotide fragments were subcloned into plasmid vector. Virus particles were collected and enveloped into HEK-293T cells.The RPE cells were infected witlh recombinant lentivirns. Real-time PCR and Western Blot were used respectively to detect the expression of HTRA 1 after lentivirus infection. Main Outcome Measures The mRNA and protein expression of HTRA 1. Results DNA sequencing demonstrated that the lentivirus shRNA vector of HTRA 1 was constructed successfully and the virus was packaged in 293 T cells.The titer of virus was 8×10^8TU/ml. The RPE cell line was successfully infected. The mRNA and protein levels of HTRA 1 were reduced sig- nificantly in RPE cells after lentivirns infection, compared with blank control and negative control. Conclusion It is concluded that the lentiviral shRNA vector of HTRA 1 is constructed, and successfully reduced HTRA1 expression in a RPE cell line.
出处 《眼科》 CAS 2013年第3期195-200,共6页 Ophthalmology in China
关键词 HTRA1 shRNA细胞 慢病毒 RNA干扰 HTRA1 gene, RPE cell lentivirus RNA interference
  • 相关文献

参考文献20

  • 1Zumbrunn J, Trueb B. Primary structure of a putative serine pro- tease specific for IGF-binding proteins. FEBS Lett, 1996, 398: 187-192.
  • 2De Luca A, De Falco M, Severino A, et al. Distribution of the ser- ine pmtease HtrA1 in normal human tissues. J Histochem Cy- tochem, 2003, 51: 1279-1284.
  • 3Zurawa-Janicka D, Skorko-Glanek J, Lipinska B. HtrA proteins as targets in therapy of cancer and other diseases. Expert Opin Ther Targets, 2010, 14: 665-679.
  • 4Chien J, Ota T, Metti G, et al. Serine protease HtrAl associateswith microtubules and inhibits cell migration. Mol Cell Biol, 2009, 29: 4177--4187.
  • 5Wang Z, Li Y, Sarkar FH. Signaling mechanism(s) of reactive oxy- gen species in Epithelial-Mesenchymal Transition reminiscent of cancer stem ceils in tumor progression. Curr Stem Cell Res Ther, 2010, 5:74 - 80.
  • 6徐莹,孙晓东.干性年龄相关性黄斑变性患者视网膜色素上皮细胞损伤机制[J].眼科新进展,2011,31(7):692-694. 被引量:7
  • 7Dewan A, Liu M, Hartman S, et al. HTRA1 promoter polymor- phism in wet age-related macular degeneration. Science, 2006, 314: 989-992.
  • 8Pulido JS, Peterson LM, Mutapcic L, et al. LOC387715/HTRAI and complement factor H variants in patients with age-related macular degeneration seen at the mayo clinic. Ophthalmic Genet, 2007, 28: 203-207.
  • 9Weger M, Rennet W, Steinbrugger I, et el. Association of the HTRA1-625 G >A promoter gene polymorphism with exudative age-related macular degeneration in a Central European popula- tion. Mol Vis, 2007, 13: 1274-1279.
  • 10An E, Sen S, Park SK, et al. Identification of novel substrates for the serine protease HTRAI in the human RPE secretome. Invest Ophthalmol Vis Sci, 2010, 51: 3379-3386.

二级参考文献42

  • 1邹海东,张晳,许迅,汪枫桦,张世杰.上海市静安区曹家渡街道年龄相关性黄斑变性的患病率调查[J].中华眼科杂志,2005,4(1):15-19. 被引量:107
  • 2Seddon JM, Chen CA. The epidemiology of age-related macular degeneration [ J ]. Int Ophthalmol Clin, 2004,44 ( 4 ) : 17 -39.
  • 3Noell WK, Walker VS, Kang BS, Berman S. Retinal damage by light in rats [ J ]. Invest Ophthalmol, 1966,5 ( 5 ) :450-473.
  • 4Tomany SC, Cruickshanks K J, Klein R, Klein BE, Knudtson MD. Sunlight and the 10-year incidence of age-related maculopathy: the Beaver Dam Eye Study [ J ]. Arch Ophthalmol,2004,122 ( 5 ) : 750-757.
  • 5Davies S, Elliott MH, Floor E,Truscott TG, Zareba M, Sarna T, et al. Phototoxicity of lipofuscin in human retinal pigment epithelial cells[ J]. Free Radic Biol Med,2001,31 (2) :256-265.
  • 6Resnikoff S, Pascolini D, Etya' ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al. Global data on visual impairment in the year 2002[ J]. Bull World Health Organ,2004,82( 11 ) :844-851.
  • 7de Jong PT. Age-related macular degeneration [ J ]. N Engl J Med ,2006,355 ( 14 ) : 1474-1485.
  • 8Friedman DS, O' Colmain B J, Munoz B, Tomany SC, McCarty C, de Jong PT, et al. Prevalence of age-related macular degenera-tion in the United States [ J ]. Arch Ophthalmol, 2004,122 ( 4 ) : 564-572.
  • 9Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY,et al. Ranibizumab versus verteporfm for neovascular age- related macular degeneration [ J]. N Engl J Med,2005,355 (14) : 1432-1444.
  • 10Rosenfeld P J, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration[ J]. N Engl J Med,2005,355 ( 14 ) : 1419-1431.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部